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Abstract
The identification of the two most prevalent susceptibility genes in breast cancer, BRCA1 and BRCA2, was the beginning of a
sustained effort to uncover new genes explaining the missing heritability in this disease. Today, additional high, moderate
and low penetrance genes have been identified in breast cancer, such as P53, PTEN, STK11, PALB2 or ATM, globally
accounting for around 35 percent of the familial cases. In the present study we used massively parallel sequencing to
analyze 7 BRCA1/BRCA2 negative families, each having at least 6 affected women with breast cancer (between 6 and 10)
diagnosed under the age of 60 across generations. After extensive filtering, Sanger sequencing validation and co-
segregation studies, variants were prioritized through either control-population studies, including up to 750 healthy
individuals, or case-control assays comprising approximately 5300 samples. As a result, a known moderate susceptibility
indel variant (CHEK2 1100delC) and a catalogue of 11 rare variants presenting signs of association with breast cancer were
identified. All the affected genes are involved in important cellular mechanisms like DNA repair, cell proliferation and
survival or cell cycle regulation. This study highlights the need to investigate the role of rare variants in familial cancer
development by means of novel high throughput analysis strategies optimized for genetically heterogeneous scenarios.
Even considering the intrinsic limitations of exome resequencing studies, our findings support the hypothesis that the
majority of non-BRCA1/BRCA2 breast cancer families might be explained by the action of moderate and/or low penetrance
susceptibility alleles.
Citation: Gracia-Aznarez FJ, Fernandez V, Pita G, Peterlongo P, Dominguez O, et al. (2013) Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2
Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles. PLoS ONE 8(2): e55681. doi:10.1371/journal.pone.0055681
Editor: Amanda Ewart Toland, Ohio State University Medical Center, United States of America
Received September 12, 2012; Accepted December 28, 2012; Published February 8, 2013
Copyright:  2013 Gracia-Aznarez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: FSMH is supported by the Dutch Cancer Society (project UL 2009-4388). The Australian Breast Cancer Family Registry (ABCFR; 1992–1995) was
supported by the Australian NHMRC, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia). The Breast Cancer Family
Registry (BCFR) was supported by the National Cancer Institute, National Institutes of Health under RFA # CA-06-503, and through cooperative agreements with
members of the BCFR and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center
(U01 CA69631), Huntsman Cancer Institute (U01 CA69446), Cancer Prevention Institute of California (U01 CA69417), University of Melbourne (U01 CA69638) and
Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). MCS is a NHMRC Senior Research Fellow and Victorian Breast Cancer Research
Consortium (VBCRC) Group Leader. JLH is a NHMRC Australia Fellow and VBCRC Group Leader. The Instituto Catalan de Oncologia (ICO) was granted by
Asociacio´n Espan˜ola Contra el Ca´ncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of
Catalonia. Contract grant numbers: ISCIIIRETIC RD06/0020/1051, PI10/01422, PI10/00748 and 2009SGR290. The Hospital Clinico de San Carlos (HCSC) was
supported by Instituto de Salud Carlos III, Fondo de Investigacio´n Sanitaria (FIS) Research Grant 09/00859 to MdH. Red Tema´tica de Investigacio´n Cooperativa en
Ca´ncer; Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (RETICC 06/0020/0021) supported TC, and MdH. The Spanish National Cancer Research
Center (CNIO) was supported by Asociacio´n Espan˜ola Contra el Cancer (AECC), Fondo de Investigaciones Sanitarias (FIS) Research Grant IP08-1120, RETICC RD06/
0020/1106. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e55681
Competing Interests: JMRR works in the company Sistemas Genomicos, but this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data
and materials.
* E-mail: jbenitez@cnio.es
Introduction
From the original publication of the two most widely known
breast cancer (BC) susceptibility genes, namely BRCA1 and BRCA2
[1,2], there has been an active pursuit of new genes contributing to
the familial BC phenotype. Additional high penetrance genes have
been identified for this disease, such as P53, PTEN or STK11
[3,4,5], however their number is not yet as high as originally
expected. Fanconi Anemia (FA) pathway genes have also been
found implicated in BC as moderate penetrance genes, given their
incomplete segregation in affected families. Such is the case of
PALB2, BRIP1, RAD51C and XRCC2 [6,7,8,9], which present
similar penetrance to other non-FA genes like ATM, CHEK2,
RAD51D and RAD51B [10,11,12,13]. Finally, 21 low risk alleles
(odds ratio (OR) between 1.1 and 1.3) identified mainly through
GWAS studies [14,15,16,17,18,19] complete the picture of known
BC susceptibility genes to date. However, all of the variants
described so far account for less than 35 percent of familial risk of
BC, leaving ample room for uncovering additional germline
mutations that confer risk of this disease.
In this regard, linkage analysis has been one of the most
widespread techniques for the identification of susceptibility genes.
Our group presented one such study in 41 BC families, which
revealed three genomic regions of interest [20]. This and other
linkage studies have found evidence for more than 20 genomic
regions in BC, but none have reached conventional levels of
evidence to be validated as true BC susceptibility loci, suggesting a
high degree of genetic heterogeneity as well as the need for new
approaches to isolate single causal genes.
Massively parallel sequencing was demonstrated to be a good
strategy for the identification of genes responsible for monogenic
diseases [21,22,23] or diseases with a high degree of genetic
heterogeneity [24]. The latter would apparently be the case for
breast and ovarian cancer syndromes, where each of the identified
genes belonging to the FA or other DNA repair pathways explain
around 1% of the families with the disease. However, a third
option in the form of a polygenic model of inheritance needs to be
taken into consideration, especially since this scenario would
represent a challenge for the identification of novel susceptibility
genes using common massive resequencing strategies. Therefore,
careful study design based in either specific phenotypic charac-
teristics or differentially expressed tumoral findings needs to be
implemented for efficacy in whole exome sequencing analysis.
In the present study we employed massively parallel sequencing
technology to investigate 7 families with at least 6 women (between
6 and 10) bearing unilateral and/or bilateral BC, previously tested
negative for BRCA1/BRCA2 mutations and younger than 60 y/o.
Here, we found several rare variants that could putatively act as
BC susceptibility genes but we also highlight the lack of evidence
of novel high penetrance genes in this disease.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all patients
included in this study. The research project was approved by
the following ethics committees: Instituto de Salud Carlos III
Ethics Committee (Spain), Fondazione IRCCS Istituto Nazionale
Tumori Ethical Committee (Italy), Human Research Ethics
Committee of the University of Melbourne (Australia), Comite´
E´tico de Investigacio´n Clı´nica del Hospital Clı´nico San Carlos de
Madrid (Spain), Human Research Ethics Committee of Bellvitge
University Hospital (Spain), Creighton University Ethics Commit-
tee (US), Medical Ethics Committee of the Leiden University
Medical Center (The Netherlands).
Family/sample Selection
Families from five countries (France, Italy, Netherlands,
Australia and Spain), including several BC-affected individuals,
were evaluated for the present study. Seven families were finally
selected based on having at least 6 BC cases (between 6 and 10)
diagnosed before the age of 60, being negative for mutations in
BRCA1 and BRCA2 genes and having no women affected with
ovarian cancer in the family. When possible, genomic DNA
samples from two individuals per family were selected for whole
exome sequencing, while samples from additional individuals in
the family were obtained for further validation (Figures S1 and
S2).
For case control association studies we selected index cases from
3694 high risk breast/ovarian cancer families without deleterious
mutations in BRCA1 or BRCA2 (named BRCAx families). Briefly,
families contained at least three females affected with breast cancer
or at least two first-degree females affected with breast cancer (at
least one of them diagnosed before 50) or at least one case of
female breast cancer and at least one case of either ovarian, female
bilateral breast or male breast cancer. Control population
consisted of DNA samples from 3960 women aged between 25
and 65 years and without personal or familial antecedents of any
cancer cases. Controls proceeded from the different countries and
their distribution is shown in Table S1.
Exome Capture/massively Parallel Sequencing
DNA samples from eleven cases (Figures S1 and S2) and seven
controls (HapMap cell lines Na11881, Na12144, Na12750,
Na12761, Na12763, Na12813 and Na12892; Coriell Cell Repos-
itories) were captured and enriched using SureSelect Human All
Exon Kit (Agilent Technologies). Enriched samples were se-
quenced on an Illumina Genome Analyzer II, using two lanes per
sample and 78 base-pair, paired-end technology (ArrayExpress
accession E-MTAB-1172). Illumina’s Real Time Analysis software
version 1.6 (with standard parameters) was used for real-time
sequencing image analysis and base calling.
Next Generation Sequencing Analysis Pipeline
Raw sequencing data for cases and controls was first filtered to
remove those reads with (1) no base called in more than 5 positions
and (2) having called the same base in more than 70% of the total
read length. After filtering, reads were aligned against the human
reference genome (hg18) using Novoalign version 2.06.09 (www.
novocraft.com) applying standard parameters except for the
option of reporting three alignments where multiple alignment
sites were found. Those reads not meeting Novoalign’s quality
criteria or not matching the reference genome were removed.
Samtools version 0.1.8 [25] was then used for PCR duplicate
removal as well as for SNP and short INDEL calling in the exomic
region. Two scores, namely Depth Score (DS) and Quality Score
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(QS), were calculated (where possible) as a ratio of the read depth
and the Phred Scaled Quality respectively between the variant and
reference alleles in a percentage format.
INDELs and heterozygote SNP variants were selected and
filtered according to the following criteria:
(1) Being common to both sequenced members of the same
family (where 2 individuals of the same family were available).
(2) Not being present in any of the 7 HapMap controls.
(3) Not being present in dbSNP130.
Remaining variants were annotated using Annovar [26] and
filtered by functional consequence (e.g. variants identified as
intronic, intergenic or synonymous were discarded). Finally, strong
candidate variants were obtained after filtering by gene function,
focusing on those genes with a potential role in cancer, and score:
(a) SNPs were filtered by DS and QS, selecting those with a DS
and QS between 20 and 210.
(b) INDELs were filtered by DS ,140, Phred Scaled Quality
.10, SNP Quality .10 and having at least 3 reads
supporting each reference and variant alleles.
In order to set up our score filtering criteria, SNPs and INDELs
from the seven HapMap controls already present in dbSNP130
were selected. Several combinations of scores were tested for
selecting the highest possible number of variants present in
dbSNP130, while targeting the lowest number of total variants
detected. For SNPs, the selected combination of scores targeted
over 95% of the total number of SNPs detected, while for indels
the percentage was reduced to 22% due to the high number of
false positive calls in our unfiltered indel data set.
Candidate variants obtained after all the filtering steps were
prioritized by Fisher’s Exact Test p value, OR value, segregation
and control population studies as described in the text.
Specificity and Sensitivity in Variant Detection
Sensitivity confirmation analysis for our pipeline, in the form of
several modifications to the standard variant filtering strategy,
were performed in order to validate the best possible sensitivity for
candidate variant detection. These modifications included:
(1) Manual re-analysis of all variants in every family after
removing variant type and gene filters.
(2) Contrasting our set of unfiltered SNP variants against those in
1000 Genomes Project. Common variants presenting minor
allele frequencies (MAF) below or equal to 1% were reviewed
to guarantee no potential causal variants were missed in the
original dbSNP130 filtering step.
(3) All stop, frameshift and splicing variants regardless of gene
and score filters were re-analysed.
(4) Our unfiltered set of variants was matched against some of the
latest identified risk modifier variants in BC, while all variants
in moderate penetrance genes XRCC2, RAD51C, RAD51D,
PALB2, BRIP and other DNA repair genes were investigated
in greater detail.
(5) Interesting variants not shared by both individuals in those
families with two individuals available for massively parallel
sequencing were evaluated. This was conceived as a
confirmation test to rule out the possibility of having selected
a phenocopy for our initial sequencing analysis in one of the
families.
Variant Validation Studies
All candidate variants were manually matched against the latest
available version of Ensembl (www.ensembl.org) for further
information and validated by Sanger sequencing.
Segregation studies were performed in additional non-next
generation sequenced individuals in each family. Basically, target
regions including the variants of interest were amplified by PCR
technology using a suitable primer pair and Sanger sequenced.
Sequencing results were evaluated with the help of Finch TV trace
viewer (Geospiza).
Figure 1. Summary of the data analysis pipeline followed in the
present study. Raw sequencing data was screened for common
artifacts prior to the alignment step in a first quality control phase
(QC1). High quality (QC2) genome matches were analyzed for variants,
in the form of departures from a consensus reference genome.
Subsequently, variants were filtered by keeping those common to
both members in each family and then discarding variants present in
HapMap controls and dbSNP130. Further filtering by variant conse-
quence, score and gene function (see material and methods for details)
resulted in a list of 67 snps and 14 indel candidate variants.
doi:10.1371/journal.pone.0055681.g001
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Genotyping in the control collection was done by dHPLC
screening or TaqMan (Applied Biosciences). Briefly, appropriate
amplification primers were designed for a genomic region
containing the variant of interest. Then, genomic control DNA
from individuals without familial BC antecedents was PCR
amplified and analysed by dHPLC as previously described [27].
DNAs corresponding to chromatography patterns departing from
that of an internal control (which does not present mutations in the
fragment of interest), were further studied by Sanger sequencing.
In those cases where TaqMan was the technique of choice, custom
probes were ordered directly from Applied Biosciences and used
according to standard protocol. Results were obtained on a
7900HT Sequence Detection System (Applied Biosciences) and
analyzed using SDS 2.4 allelic discrimination software.
Case control studies were performed either using TaqMan
genotyping assays or TaqMan OpenArray technology (Applied
Biosciences). Genotyping using TaqMan assays was performed as
previously described, this time including both familial BC affected
(cases) and non-affected (control) individuals. TaqMan OpenArray
technology was used for large scale genotyping. Briefly, 64 SNP
array format was selected to genotype 56 variants of unknown
significance in 2693 cases and 2544 controls from different ethnic
origin coming from various centers from the BC consortium.
Issues with custom probe design and cluster discrimination in
specific probes reduced the final number of informative variants to
39. A total of 130 arrays were performed and analyzed uniformly
according to the manufacturer’s standard protocol. HapMap and
sample duplicates were included in each array to serve as internal
controls and to ensure reproducibility of the results. Genotype
calling and sample clustering for OpenArray assays was performed
in TaqMan Genotyper Software v1.0 (Applied Biosciences).
Statistical analysis of the data was done using PLINK software
[28], where Fisher’s Exact Test p-values, OR and 95% confidence
intervals for the OR were computed.
Predictive Programs
The potential functional impact of the non-synonymous variants
detected in this study was inferred based on predictions made by
SIFT [29] and PolyPhen [30]. Pathogenicity of variants that were
located in intronic positions that could potentially affect the
splicing process was predicted based in the algorithms integrated
in the software Alamut 2.0 (SpliceSiteFinder-like, MaxEntScan,
NNSPLICE and Human Splicing Finder).
Results
Eleven individuals from 7 families and 7 HapMap cell lines,
serving as internal and filtering controls, were analyzed by
massively parallel sequencing in this study. Results including
number of reads, sample coverage and sequencing depth have
been summarized in Table S2.
The bioinformatics analysis and variant filtering pipeline was
developed by our group and recently used in the identification of a
novel familial pheocromocytoma gene [24]. The main steps are
represented in Figure 1. After applying this filtering pipeline, an
initial set of 67 (average of 10 per family) SNPs and 14 INDELs
(average of 2 per family) passed all the filters (Tables 1 and 2).
First, we focused on a group of 25 high interest candidate
variants including 12 indels, 3 stopgains, and 6 splicing variants.
Additionally, 4 non-synonymous SNPs were included in this group
because they either were present in two families (FANCM,
CNTROB) or affected a P53-related gene, TP53I13 (Table S3).
Validation of the final candidates was done by Sanger sequencing
Table 1. SNP Filtering Summary.
Sample
Detected
heterozygous
SNPs
Common
within a family
Not present in 7
HapMap Controls
Not present
in dbSNP130
After variant
consequence
filtera
After score and gene
function filtersb
07S240 (Pedigree 49) 29549 29549 9451 3838 1000 67d
DAD_1 (Pedigree 694) 28697 28697 9144 3666 899
F2887_13 (Pedigree
2887)
28978 9271c 1681c 404c 156c
F2887_24 (Pedigree
2887)
30691
F3311_5 (Pedigree
3311)
26774 8776c 1686c 328c 100c
F3311_43 (Pedigree
3311)
26468
I_1408 (Pedigree 531) 28841 28841 9022 3553 971
RUL036_2 (Pedigree RUL036) 27060 11405c 2746c 776c 188c
RUL036_7 (Pedigree RUL036) 27032
RUL153_2 (Pedigree RUL153) 26908 8295c 1373c 197c 53c
RUL153_3 (Pedigree RUL153) 27406
Average 28249 17833 5015 1823 481 10
Percentage remaining 100 63.13 17.75 6.45 1.70 0.04
Variant filtering representation through the number of SNPs remaining after the various filtering steps.
The Average and Percentage remaining rows represent the average number of variants and percentage of variants remaining per family.
aIntronic, intergenic and synonymous variants were discarded. See methods.
bDetailed criteria for these filters is reported on the methods section.
cNumber of variants shared between the two individuals in the family.
dTotal number of final variants for all the individuals in this study.
doi:10.1371/journal.pone.0055681.t001
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and segregation. Then, we performed segregation studies in other
affected members of the same family from whom DNA was
available (an average of 2–4 additional members/family except in
family 694). Furthermore, those variants segregating in over 50%
of the available individuals in each family were tested in a pool of
up to 750 Spanish control women.
One of the variants identified in Family RUL153 was a deletion
in CHEK2 (c.1100delC), a gene already described as a moderated
susceptibility gene [11]. We extended the study to two additional
affected members in this family and found that one of them (I-1)
didn’t present the same mutation (Figure S1). The non-carrier
showed an elevated diagnostic age (76 years old) when compared
to the rest of the affected carrier individuals, so a haplotype
analysis was performed and helped to confirm this individual as a
phenocopy (data not shown).
FANCM was mutated in families 694 and 531 (Figure S1). The
former family carried the p.Arg1931 stop mutation (c.5791C.T)
annotated as rs144567652 while the latter carried a non-
synonymous mutation (c.4392A.T), both of them validated by
Sanger sequencing. However, a segregation analysis discarded the
variant in family 531 as a plausible BC related allele (Table S3).
We then centered our study on the stopgain variant in FANCM,
since some genes from the Fanconi pathway have already been
described as BC susceptibility genes [31]. Given that segregation
studies were not feasible in this family, in order to analyze the
possible effect of this variant we performed a case control
association study by TaqMan, including 3409 BRCAX cases
and 3896 controls from Italy, Netherlands, Australia and Spain
(Table S1). We found 10 positive cases and 5 positive controls,
with an estimated OR = 2.29 (95%CI = 0.71–8.54), p = 0.13.
Other candidate variants segregating in more that 50% of the
individuals in our families such as SOSTDC1 (c.664delA) (family
49, involved in cellular proliferation, differentiation, and pro-
grammed cell death); CNTROB (c.2081A.G, rs139292572)
(family 3311, a centrosomal BRCA2 interacting protein) and
HSP90B1 (c.2362_2364delGAA, rs5800607) (family 3311, codify-
ing for a heat shock protein), were discarded for being present in
control population with a MAF .1% (Table S3). On the other
hand, SLBP (c.697G.A) (a stem-loop binding protein) and
CNTROB (c.1819G.A), both in family RUL036, were not found
in the same set of controls. A splice site variant in the oncogenesis-
involved WNT8A (c.103G.T) gene was found in family 694. We
were unable to confirm experimentally whether the variant altered
the splicing, due to a very low expression level of the gene in
fibroblasts (data not shown). However, after performing a case-
control study by TaqMan in 2043 BRCAx cases and 2186
controls, none of the 4229 samples were found to carry the same
variant. Ultimately, four rare variants were selected from the
group of 25 high interest variants: FANCM (c.5791C.T,
stopgain), SLBP (c.697G.A, splicing), CNTROB (c.1819G.A,
missense) and WNT8A (c.103G.T, splicing).
We then focused on the analysis of the remaining 56 missense
variants of unknown significance, not previously described in
ensemble database and predicted to be deleterious or probably
damaging in at least one of the two predictive programs, SIFT
[29] and Polyphen [30]. In order to evaluate their role in cancer
susceptibility, the variants were genotyped in 2693 BRCAx cases
Table 2. INDEL Filtering Summary.
Sample
Detected
INDELs
Common
within a family
Not present in 7
HapMap Controls
Not present in
dbSNP130
After variant
consequence filtera
After score and gene
function filtersb
07S240 (Pedigree 49) 36189 36189 26077 24580 11387 14d
DAD_1 (Pedigree 694) 35606 35606 25741 24204 11046
F2887_13 (Pedigree
2887)
34081 12299c 5314c 4650c 1354c
F2887_24 (Pedigree
2887)
31445
F3311_5 (Pedigree
3311)
30983 12442c 4982c 4340c 579c
F3311_43 (Pedigree
3311)
26441
I_1408 (Pedigree 531) 36131 36131 26082 24591 11352
RUL036_2 (Pedigree
RUL036)
25162 13042c 5087c 4398c 587c
RUL036_7 (Pedigree
RUL036)
25652
RUL153_2 (Pedigree
RUL153)
25698 11878c 4445c 3834c 506c
RUL153_3 (Pedigree
RUL153)
26045
Average 31526 22512 13961 12942 5259 2
Percentage remaining 100 71.41 44.28 41.05 16.68 0.01
Variant filtering representation through the number of INDELs remaining after the various filtering steps.
The Average and Percentage remaining rows represent the average number of variants and percentage of variants remaining per family.
aIntronic and intergenic variants were discarded. See methods.
bDetailed criteria for these filters is reported on the methods section.
cNumber of variants shared between the two individuals in the family.
dTotal number of final variants for all the individuals in this study.
doi:10.1371/journal.pone.0055681.t002
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and 2544 controls using an Open Array platform (Applied
Biosystems). Technical problems during custom design, as well
as discrimination issues in the analysis of specific probes reduced
the number of variants finally evaluated to 39. Table S4 includes
genotyping-related information on genes, frequencies, OR and p
values.
From the previous group of 39 variants, we selected for further
validation those variants with an estimated OR higher than two or
not present in controls. Thirteen variants fulfilling these criteria
were Sanger-validated and analyzed for segregation in their
original families (except for variants in family 694) (Table S5). Five
variants (in addition to two from family 694) were validated and
showed segregation in at least 50% of the available individuals. We
consider these seven variants as well as the previous four
candidates our potential rare variants candidate to play a role in
familial BC development (Table 3).
Discussion
The present study was designed to identify new high suscep-
tibility genes in familial BC. Family selection was based in the
highest possible number BC cases per family under the age of 60 (6
to 10 cases through generations), while having no other tumor
types segregating in the family. As proposing candidates relying on
next generation sequencing results alone is not sufficient evidence,
segregation, control population and case-control studies were
performed to gain further insight on the relevance of the proposed
candidates in BC.
A total number of 81 variants, 67 snps and 14 indels, were
identified as potential candidates after applying our filtering
protocols. These were subdivided into two groups to facilitate the
analysis, a first group containing mainly putative protein
truncating variants or variants shared between several families
and a second group of rare missense mutations. Among those in
the first group, we detected a previously identified moderate
susceptibility indel variant in CHEK2 (c.1100delC) in family
RUL153 (Figure S1), which served to confirm the adequacy of our
filtering strategy for the detection of known BC-related variants.
Additional variants were also analyzed in this first group.
FANCM variant c.5791C.T generates a premature stop codon,
originating the loss of 118 aminoacids from the c-terminal end of
the main transcript and putatively influencing FANCD2 mono-
ubiquitination. A case control study in a cohort of over 7300
samples revealed an OR = 2.29 and a non-significant Fisher’s
Exact Test p value (p = 0.13). However, given the low frequency of
this variant (0.0011 in cases and 0.00077 in controls), its variable
prevalence in the available populations (0.6% in the Italian, 0.3%
in the Spanish, but not found in the Netherland samples and found
once (0.14%) in the Australian controls, data not shown) and
FANCM’s important role in DNA repair, it would be interesting to
analyze this gene in a higher number of samples to fully
understand its contribution to BC. Also, hints of a possible link
with BC were found for BRCA2 interacting CNTROB
(c.1819G.A), SLBP (c.697G.A) and WNT8A (c.103G.T).
Those presented a high level of familiar segregation in the
available individuals (greater than 50%) and absence of the variant
in over 700 controls (CNTROB and SLBP) or in over 4000 samples
(WNT8A), similarly to what could be expected for rare suscepti-
bility variants (Table S5).
To explore the role of the 56 identified missense mutations, we
performed a case-control association study in over 5200 samples
(BRCAx cases and controls), a large enough cohort to obtain a
preliminary idea of association with BC. Since we discarded
variants with a MAF higher than 1% and only rare variants were
considered after this point in the analysis, we did not have enough
statistical power or we could not calculate it in those variants
present in neither cases nor controls. Therefore, we selected
variants with a high probability of being linked with cancer by
prioritizing variants with OR higher than 2 or absent in controls, a
damaging predicted functional impact and segregating in over
50% of the available individuals in each family. Our final
candidates include 7 variants in genes related with cell survival,
proliferation, angiogenesis, cell cycle progression, cell adhesion
and other roles plausibly related to cancer development and
progression (Table 3). These genes are candidates to be studied by
targeted resequencing in a large series of cases (BRCAx) and
controls in order to assess their role in familial cancer suscepti-
bility. In this regard, based on the current evidence, we cannot
conclude that these variants are pathogenic and they should not be
added to mutation databases as pathogenic variants based solely
on the data presented here.
As our families were selected for the high number of affected
women across generations and their seemingly dominant model of
inheritance, our results were unexpected. However, two recent
whole exome studies were also unsuccessful in finding novel high
penetrance genes in BC, pointing our result towards a more
common scenario in this disease. While selecting their families
with less strict criteria, Snape et al [32] sequenced 50 BRCAx
probands to find no high susceptibility genes. More recently,
Thompson et al [33] found two new genes by whole exome
sequencing, FANCC and BLM, which would be mutated in
approximately 0.5% of BRCAx families. Both studies also
suggested a number of rare variants to be analyzed further in
future studies.
A number of limitations in the present study need to be taken
into consideration. The number of individuals/families selected for
this re-sequencing study is smaller than that of similar studies.
While this approach might limit the number of potential candidate
variants detected as compared to other less stringent family
selection strategies [32], it is a reflection of the small number of
non-BRCA1/2 families presenting a high number (from 6 to 10) of
BC events per family, which in turn represents a highly desirable
starting point for the identification of novel high penetrance genes
in any disease. Additionally, the observed phenotype in our
families could be related to undetectable alterations using the
current approach: mutations in regions outside the captured
genomic pool, undetected alterations due to alignment/variant
calling errors or those presenting insufficient evidence to pass the
filtering criteria. When possible, this and other potential pitfalls in
this study, such as rejecting mutations for being in less well known
regions (e.g. introns), discarding causal variants for being present
in the databases or choosing a phenocopy for the initial re-
sequencing in one of the families, were taken into consideration. In
this regard, the filtering strategy was conceived to prioritize
sensitivity while using filtering principles widely applied in
successful massively parallel sequencing studies [24,32,34,35].
The fact that low stringency filtering thresholds paired to the use of
alternative analysis to assess the efficacy of most of our filtering
steps (see methods) yielded no additional potential candidates
further supports our results.
Finally we cannot rule out that some of these families shift a
putative explanation towards a polygenic model where moderate
and low penetrance alleles would play a predominant role. This
hypothesis has been suggested by different authors [36,37] mainly
based in linkage analysis, modeling or targeted resequencing [38]
due to the lack of success in finding high susceptibility genes even
in regions with statistically significant lod scores. Nowadays, new
technologies like massively parallel sequencing in stringently
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selected families, as in our case, support it from a practical point of
view. An example of this is a recent paper by Sawyer et al [39]
showing how women affected by familial BC had a highly
significant excess of risk alleles compared with controls. Unfortu-
nately, due to the small number of cases in our study we could not
analyze this issue.
According to the presented data, families fulfilling the criteria of
high risk for BC and including several affected women across
generations show evidence of a high genetic heterogeneity and
complexity. In this context, some families would be explained
based in a polygenic model where rare variants would play an
interesting role in BC susceptibility.
Further studies in a larger number of families, using a combined
strategy of whole exome/whole genome sequencing, case-control
association studies including thousands of samples and targeted
resequencing of genomic regions containing rare variants is
needed to confirm these preliminary results and to define the
genetic architecture of non-BRCA1/2 BC families.
Supporting Information
Figure S1 Pedigrees of families included in this study I.
Pedigrees 694, RUL153 and 531 are represented in this figure.
Arrows indicate individuals selected for massively parallel
sequencing. Cancer affected individuals are partly or totally
highlighted in black. Br sign followed by a number under affected
individuals marks the age of diagnostics of each breast cancer
event. Deceased individuals are marked by a slash. Arabic
numbers refer to those members used for segregation. UL = Uni-
lateral breast cancer. BL = Bilateral breast cancer.
(TIF)
Figure S2 Pedigrees of families included in this study
II. Pedigrees 3311, RUL036, 49 and 2887 are represented in this
figure. Arrows indicate individuals selected for next generation
sequencing. Cancer affected individuals are partly or totally
highlighted in black. Br sign followed by a number under affected
individuals marks the age of diagnostics of each breast cancer
event. Deceased individuals are marked by a slash. Arabic
numbers refer to those members used for segregation. UL = Uni-
lateral breast cancer. BL = Bilateral breast cancer.
(TIF)
Table S1 Clustering of Validation Samples by Country
of Origin. Distribution of samples and controls used for the
different case-control studies and validation analysis by TaqMan
and OpenArray. FANCM was studied with samples from 1–6.
WNT8A was studied with samples 1, 2, 4 and 5. OpenArray:
samples from 1–5. CNIO control samples were used for validation
of variants in Table S3. aSpanish National Cancer Research
Centre (Spain). bHospital Clinico San Carlos (Spain). cHospital
Universitario Valladolid (Spain). dLeiden University Medical
Center (Netherlands). eIstituto Nazionale dei Tumori (Italy). dThe
University of Melbourne (Australia).
(DOC)
Table S2 Next Generation Sequencing Metrics and
Coverage. Next generation sequencing results per sample.
aSequence stands for the number of bases sequenced per
individual. bNumber of genomic matches refers to the number
of genomic locations aligning to the total number of reads in a
given sample. The option of reporting up to 3 alignment positions
on conflicting matches increases this number with regard to the
total number of reads. cOn-target refers to the total number of
reads on target. dPaired end column represents the number of on-
target positions successfully aligned as paired-end reads.
(DOC)
Table S3 Candidate Variants I: Potential Protein Trun-
cating, Splicing Variants and Indels. List of 25 potential
protein truncating or splicing variants, indels and variants of
unknown significance in genes shared by different families. In
bold, selected variants. aPosition according to the coordinate
system (HG18). bSanger sequencing validation. cResults of
segregation studies marking positive individuals out of the total
number available for validation. dControl population studies were
performed in variants segregating in over 50% of the available
individuals for validation. Figures represent the number of positive
cases out of the total number tested, as well as the percentage of
positive cases in the population. eMinor Allele Frequency reported
in 1000 Genomes Project (May 2011 release). N/A = not available.
NV = non validated.
(DOC)
Table S4 List of Variants Analyzed by Open Array Case-
control Design and Results. List of variants analyzed by Open
Array case-control design. In bold, selected candidates. aChromo-
some where the variant was mapped. bPosition according to the
coordinate system (HG18). cVariant consequence: NS = non-
synonymous variant UTR3 = 39 untranslated region variant.
dFisher’s Exact Test P value. eOdds Ratio. f95% confidence
interval for the Odds Ratio. gMinor Allele Frequency reported in
1000 Genomes Project (May 2011 release). N/A = not available.
(DOC)
Table S5 Candidate Variants II. Open Array Variants with
an OR higher than 2 or absent in control population. In bold,
selected candidates. aPosition according to the coordinate system
(HG18). bVariant consequence. UTR3 = variant is located at the
39 untranslated region. NS = non-synonymous variant. cSanger
sequencing validation. dResults of segregation studies stating the
number of positive individuals out of the total number available for
validation in the family. eSHIFT/Polyphen predictions: D = Dam-
aging PD = Probably damaging T = Tolerated.
(DOC)
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